



SOLVER for Pharmaceutical Companies

| Get Complete Insight

Updated: Jan/2020

www.solverglobal.com

Solver, Inc. | Copyright © 2020

Table of Contents

Introduction.....	1
Product Summary.....	1
Company Summary.....	2
PHA02 – Executive Dashboard.....	3
PHA03 – Sales Management Dashboard.....	4
PHA04 – Patient Assistance Dashboard.....	5
PHA05 – Reimbursement Program Dashboard.....	6
PHA06 – Drug Trials Dashboard.....	7
PHA07 – Profit and Loss Report.....	8
PHA08 – Balance Sheet Report.....	9
PHA09 – Cash Flow Report.....	10
Appendix – Terminology Used in Examples.....	12

Introduction

The purpose of this white paper is to provide an overview of Solver. With frequent, automated cloud updates, the solution is continuously being enhanced to drive faster, better decisions across its global customer base. For the latest information or to discuss your specific needs, please contact your local Solver partner, visit Solver's [web-site](#) or email us at info@solverglobal.com.

Product Summary

Solver provides a single, cloud-based solution that automates reporting and planning processes, and supports faster and better decisions based on key information from across the organization's data sources.

Key benefits that Solver provides include:

- A top-rated Corporate Performance Management (CPM) solution by G2 based on user satisfaction
- Global partner channel with industry expertise to help you whenever and wherever
- Cloud software, support, and upgrades packaged into a subscription price providing unmatched ROI over traditional CPM solutions
- Built for business users to manage the entire solution without the need for developers
- Executive and management data from across the organization that is easily accessible in ONE place with Solver's intelligent data warehouse
- Solver's multi-tenant cloud application provides quick initiation, SOC 2 compliance, automatic software upgrades, and scalability at one's convenience
- Solver provides the power and the familiarity of cloud-connected Excel to solve the most complex formula and layout requirements for reporting and planning template designers
- Easy-to-use, pre-built integration to Power BI, the world's #1 visualization solution
- Fast and cost effective integrations provided with Solver's wizard-driven CSV, SQL, and prebuilt ERP/CRM Connectors
- Unlimited access to reports and dashboards from secure web portal
- Hybrid cloud option provides customers with real-time cloud reporting capabilities for their on-premise ERP system



Company Summary

Solver, Inc. is redefining the category of cloud-based reporting and planning. The Solver solution is built to enable faster and better business decisions across the entire organization. Solver combines financial and other key data into a single tool, powered by the most flexible report and planning form designer on the market. Organizations use this solution to automate and streamline financial and operational reports, consolidations, and budgeting and forecasting processes. Solver empowers users with complete insight that drives intelligent decisions and competitive advantages. Headquartered in the United States, Solver, Inc. has more than a dozen offices and hundreds of partners globally that provide local and industry expertise. To learn more, visit www.solverglobal.com.

PHA02 – Executive Dashboard

This is an example of an executive dashboard. It shows the use of the Solver Data Warehouse to combine numerous important data sources on a single dashboard and present whatever a company determines as the most essential information to an executive. In this sample dashboard, the following information is included:

- Top Sales Producers (Salespersons)
- Top Payers (Insurance Companies, Government etc.) on behalf of the consumer
- Top Sales Channels
- Volume by Product
- Gross and Net Sales over the last 12 months



PHA03 – Sales Management Dashboard

This dashboard example focuses on overall Sales Management, with an added focus on First Time Prescriptions (NBRx), Medication Samples distributed to providers, and the number of providers visited (reached) by the sales team.

In this sample dashboard, the following information is included:

- Sales Trend (rolling 12 month)
- Sales by Business Unit
- Sales by Channel
- Net Sales by Product
- YTD Units Sold
- New Business (NBRx) (Rolling 12 months)
- Samples by Product
- Reach (Calls on Physicians etc.) by Business Unit




PHA04 – Patient Assistance Dashboard

This dashboard example focuses on the Patient Assistance and Medical Advisory services. The Product table in the top left corner can also be used as a filter, which will automatically filter the other components in the dashboard on that Product. In this sample dashboard, the following information is included: Patient Assistance Program:

- Status of Patient Assistance Requests
- Enrollees per Patient Assistance Program Type
- Enrollees per Eligibility Criteria

Medical Advisory Services:


- Source of Medical Inquiries
- Number of Medical Inquiries by Product
- Number of Medical Inquiries by Method of Communication



PHA05 – Reimbursement Program Dashboard

This dashboard example presents a picture of the Reimbursement Program. In this sample dashboard, the following information is included:


- Cost of Reimbursements by Channel
- Number of Reimbursement Requests by Status
- Cost of Reimbursements per Product
- Number of requests per Reimbursement Channel
- Top 5 Claimants by Reimbursement Cost
- Reimbursement Costs per Product



PHA06 – Drug Trials Dashboard

This dashboard example presents a picture of Drug Trials Projects. In this sample dashboard, the following information is included:

- Target vs Actual Cost per Drug Trial
- Target vs Actual Number of Participants per Drug Trial
- Target vs Actual Number of Hours spent per Drug Trial
- Target vs Actual Cost by Drug Trial Milestone Status



PHA07 – Profit and Loss Report

This Solver report example shows a formatted Profit & Loss Report. Solver's flexible report designer can design virtually any financial statement. The example below includes key figures in large fonts to draw the reader's attention to the most important information in the report. Users can drill down to analyze the details behind the numbers.


As with all Solver reports, filters can be used to run the report for any time-period, customer, item, etc. In addition, the report can be run and published by email, or run on-demand in Excel, the Web Portal or on a Mobile device.

PROFIT & LOSS									
Company: S. America									
September, 2021									
	Act Mth	Act Mth LY	Var	Var %	Bud Mth	Var %	Act Ytd CY	Act Ytd LY	Variance
Revenue									
40010 Product Revenue	415,116	522,948	(107,833)	-20.6%	214,722	93.3%	3,556,653	(211,123)	3,767,775
40020 Services Revenue	276,143	326,352	(50,209)	-15.4%	142,837	93.3%	2,125,542	(154,553)	2,280,095
40030 Royalties Revenue	33,020	46,635	(13,616)	-29.2%	17,080	93.3%	318,201	(22,110)	340,311
40040 Other Revenue	13,887	19,474	(5,587)	-28.7%	7,183	93.3%	141,893	(10,965)	152,859
Total Revenue	738,166	915,410	(177,244)	-19.4%	381,822	93.3%	6,142,289	(398,752)	6,541,040
Cost of Goods Sold (COGS)									
50010 COGS - Product Sales	70,778	111,318	(40,540)	-36.4%	70,778	0.0%	70,778	90,822	(20,045)
Total COGS	70,778	111,318	(40,540)	-36.4%	70,778	0.0%	70,778	90,822	(20,045)
Gross Revenue	667,388	804,092	136,704	17.0%	311,044	-114.6%	6,071,511	(489,574)	6,561,085
Gross Profit Margin	90.41%	108.93%	18.52%	17.0%	42.14%	-114.6%	822.51%	-66.32%	888.84%
Expenses									
<i>Administration</i>									
Salaries and Benefits	34,232	42,288	8,055	19.0%	34,232	0.0%	34,232	38,526	4,293
Sales and Marketing	39,175	48,630	9,455	19.4%	39,175	0.0%	39,175	49,234	10,059
Travel and Entertainment	291	373	81	21.8%	291	0.0%	291	303	12
Professional Fees	1,990	2,555	565	22.1%	1,990	0.0%	1,990	2,282	292
Business Insurance	389	494	105	21.3%	389	0.0%	389	479	90
Office Supplies	401	624	223	35.8%	401	0.0%	401	512	112
Telephone and Internet	1,038	1,504	465	31.0%	1,038	0.0%	1,038	1,244	205
Rent and Utilities	988	1,053	65	6.2%	988	0.0%	988	991	3
Admin Expenses	1,188	1,452	264	18.2%	1,188	0.0%	1,188	1,292	104
Total Administration Expenses	79,693	98,972	19,279	19.5%	79,693	0.0%	79,693	94,863	15,171
<i>Finance & Accounting</i>									
Salaries and Benefits	19,684	30,558	10,873	35.6%	19,684	0.0%	19,684	25,920	6,236
Sales and Marketing	21,662	35,640	13,978	39.2%	21,662	0.0%	21,662	32,259	10,597
Travel and Entertainment	161	226	65	38.8%	161	0.0%	161	187	27

PHA08 – Balance Sheet Report


This Solver report example shows a formatted Balance Sheet Report. Solver's flexible report designer can design virtually any financial statement. The example below includes key figures in order to draw the reader's attention to the most important information in the report. Users can drill down to analyze the details behind the numbers.

As with all Solver reports, filters can be used to run the report for any time-period, customer, item, etc. In addition, the report can be run and published by email, or run on-demand in Excel, the Web Portal or on a Mobile device.

 Balance Sheet Report Asia		4/5/18 8:50 PM		
	September, 2021	August, 2021	December, 2020	
ASSETS				
<i>Current Assets</i>				
Cash & Equivalents	55,920	61,702	14,805	
Accounts Receivable	61,812	61,123	52,650	
Inventories - FG/WIP/Raw	18,317	18,021	14,030	
Other Current Assets	12,622	12,374	9,153	
Total Current Assets	148,671	153,219	90,638	
<i>Property & Equipment</i>				
Buildings, Land and Improvements	144,670	141,299	100,635	
Other Property, Plant & Equipment	61,606	60,303	43,832	
Computer Software and Equipment	27,618	27,104	20,017	
Accumulated Depreciation	(80,987)	(79,245)	(57,561)	
Total Property and Equipment	152,907	149,460	106,923	
Investments and Advances	60,509	59,210	41,925	
Long-Term Note Receivable	28,092	27,520	20,177	
Intangible Assets	49,246	48,291	35,407	
Other Assets	1,558	1,534	1,229	
Investment in Subsidiary				
TOTAL ASSETS	440,982	439,235	296,298	
LIABILITIES				
<i>Current Liabilities</i>				
Accounts Payable	45,894	45,096	35,942	
Current Maturities of Long-Term Debt	127,392	124,681	90,837	
Total Current Liabilities	173,286	169,777	126,779	

PHA09 – Cash Flow Report

This Solver report example shows a formatted Cash Flow Report. Solver's flexible report designer can design virtually any financial statement.

 Cash Flow Report S. America		4/5/18 8:52 PM	
	September, 2021	August, 2021	
Cash Flow from Operating Activities			
Net Income	439,544	352,169	
Adj NI to Net Cash Provided by Ops. Activities			
Depreciation & Amortization Expense	(27,596)	(30,243)	
Other Current Assets	(495)	(595)	
Non-Current Assets	(3,536)	(3,647)	
Accounts Receivable	(6,553)	(6,209)	
Accounts Payable	1,561	1,535	
Prepaid Expenses	0	0	
Net Cash Provided by Operating Activities	402,924	313,010	
Cash Flows from Investor Class			
Purchase of Property, Plant, and Equipment	(9,077)	(10,144)	
Accumulated Depreciation	359,866	394,453	
Net Cash from Investor Class	350,789	384,309	
Cash Flows from Public Entities			
Proceeds from Grants	99,010	104,725	
Net Cash from Public Entities	99,010	104,725	
Net Increase in Cash	852,724	802,045	
Cash at Beginning of Period	1,396,653	1,396,653	
Cash End of Period	2,249,377	2,198,698	
Check - Cash End of Period from Database	2,249,377	2,198,698	

PHA20 – Cost Allocation Form

This web-based input form example shows the ability in Solver to write data back to the Solver database. In this example, forecasts of cost allocations for expenses against Drug Trials are made using this interface, with the results being written back to the Solver database.

BI360 Project Cost Allocation
 N. America
 Sales
 Main Transactions
 Budget

Account	Description	Actual Amount	Jan 21	Feb 21	Mar 21	Apr 21	May 21	Jun 21	Jul 21	Aug 21
			Projected Spend	Projected Spend	Projected Spend	Projected Spend	Projected Spend	Projected Spend	Projected Spend	
60010	R&D -Develop p2 Epilepsy	\$ 81,967.21	\$ 59,333.00	\$ 48,156.00	\$ 60,903.00	\$ 51,453.00	\$ 50,091.00	\$ 53,140.00	\$ 60,946.00	\$ 59,300.00
60020	R&D -Develop p1 Oncology	\$ 5,953.41	\$ 4,608.00	\$ 4,284.00	\$ 5,328.00	\$ 3,915.00	\$ 3,520.00	\$ 4,825.00	\$ 5,952.00	\$ 4,816.00
60030	R&D -Test p2 Epilepsy	\$ 23,080.24	\$ 17,557.00	\$ 15,228.00	\$ 13,483.00	\$ 14,305.00	\$ 11,749.00	\$ 20,612.00	\$ 19,705.00	\$ 14,587.00
61010	R&D -Test p3 Ebola	\$ 9,490.94	\$ 6,548.00	\$ 4,934.00	\$ 5,392.00	\$ 4,922.00	\$ 4,373.00	\$ 7,870.00	\$ 6,645.00	\$ 6,281.00
61040	R&D -Test p1 Oncology	\$ 2,049.18	\$ 1,681.00	\$ 1,325.00	\$ 1,388.00	\$ 1,269.00	\$ 1,350.00	\$ 1,970.00	\$ 1,578.00	\$ 1,748.00
61050	R&D -Regulatory p2 Epilepsy	\$ 3,108.90	\$ 2,361.00	\$ 2,216.00	\$ 2,217.00	\$ 1,917.00	\$ 1,677.00	\$ 2,414.00	\$ 2,709.00	\$ 2,335.00
61500	R&D -Regulatory p3 Ebola	\$ 15,854.18	\$ 11,129.00	\$ 9,020.00	\$ 10,411.00	\$ 9,636.00	\$ 10,234.00	\$ 10,925.00	\$ 12,250.00	\$ 11,465.00
61510	R&D -Regulatory p1 Oncology	\$ 2,372.73	\$ 1,445.00	\$ 1,234.00	\$ 1,252.00	\$ 1,389.00	\$ 1,369.00	\$ 1,968.00	\$ 1,594.00	\$ 1,841.00
61520	R&D -Market p2 Epilepsy	\$ 2,221.74	\$ 1,510.00	\$ 1,523.00	\$ 1,419.00	\$ 1,489.00	\$ 1,165.00	\$ 1,931.00	\$ 1,916.00	\$ 1,597.00
61530	R&D -Market p3 Ebola	\$ 2,286.45	\$ 1,572.00	\$ 1,354.00	\$ 1,390.00	\$ 1,167.00	\$ 1,094.00	\$ 1,527.00	\$ 1,840.00	\$ 1,505.00
61540	R&D -Market p1 Oncology	\$ 442.39	\$ 350.00	\$ 286.00	\$ 274.00	\$ 258.00	\$ 239.00	\$ 341.00	\$ 397.00	\$ 345.00
Expenses:		\$ 148,827.37	\$ 108,094.00	\$ 89,560.00	\$ 103,457.00	\$ 91,720.00	\$ 86,861.00	\$ 107,523.00	\$ 115,532.00	\$ 105,820.00

Users can spread Cost Allocation across periods with custom spread methods:

BI360 Project Cost Allocation
 N. America
 Sales
 Main Transactions
 Budget

Account	Description	Actual Amount	Jan 21	Feb 21	Mar 21	Apr 21	May 21	Jun 21	Jul 21	Aug 21
60010	R&D -Develop p2 Epilepsy	\$ 81,967.21	\$ 59,333.00	\$ 48,156.00	\$ 60,903.00	\$ 51,453.00	\$ 50,091.00	\$ 53,140.00	\$ 60,946.00	\$ 59,300.00
60020	R&D -Develop p1 Oncology	\$ 5,953.41	\$ 4,608.00	\$ 4,284.00	\$ 5,328.00	\$ 3,915.00	\$ 3,520.00	\$ 4,825.00	\$ 5,952.00	\$ 4,816.00
60030	R&D -Test p2 Epilepsy	\$ 23,080.24	\$ 17,557.00	\$ 15,228.00	\$ 13,483.00	\$ 14,305.00	\$ 11,749.00	\$ 20,612.00	\$ 19,705.00	\$ 14,587.00
61010	R&D -Test p3 Ebola	\$ 9,490.94	\$ 6,548.00	\$ 4,934.00	\$ 5,392.00	\$ 4,922.00	\$ 4,373.00	\$ 7,870.00	\$ 6,645.00	\$ 6,281.00

Sheet1

61040 - R&D -Test p1 Oncology

Main line
 2021-01-31T00:00:00:202101 00:202102 00:202103 00:202104 00:202105 00:202106 00:202107 00:202108 00:202109 00:202110 00:202111 00:202112
 \$1,681.00 \$1,325.00 \$1,388.00 \$1,269.00 \$1,350.00 \$1,970.00 \$1,578.00 \$1,748.00 \$1,593.00 \$1,311.00 \$1,544.00 \$1,798.00 \$18,555.00

Line item details
 DESCRIPTION

Line item detail comment
 Comment

Spreading
 SPREAD ADJUST
 SPREAD AMOUNT
 50000
 USING DISTRIBUTION RULE
 Even
 SPREAD

Appendix – Terminology Used in Examples

PHA01- Benchmarking Dashboard

Benchmarking across different metrics compares the demo company to GSY, Koche and Pfizer. These fictional entities are supposed to be Pharma companies, not unlike actual firms. M&D – Manufacturing and distribution.

R&D – Research and development.

PHA03- Sales Management Dashboard

New Business – NBRx refers to prescriptions written to a distinct individual for the first time. Samples – Product left with prescribers (doctors, clinics, etc.) for distribution to patients.

Reach – Number of sales visits to prescribers.

PHA04- Patient Assistance Dashboard

Patient Assistance Programs (PAP) help individuals obtain subsidized medication. Patient Requests – Request for subsidized medication.

Enrollees – Patients accepted in the PAP.

Medical Advisory Inquiries – Advice and consultation on the medications specific use and dosing from medical professionals.

PHA05- Reimbursement Program Dashboard

Reimbursement Program – Practice of compensating medical professionals for time spent on developing the market for the product.